Warnecke-Eberz U, Plum P, Schweinsberg V, Drebber U, Bruns CJ, Müller DT, Hölscher AH, Bollschweiler E. Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients. World J Gastroenterol 2020; 26(23): 3236-3248 [PMID: 32684738 DOI: 10.3748/wjg.v26.i23.3236]
Corresponding Author of This Article
Ute Warnecke-Eberz, PhD, Professor, Department of General, Visceral and Cancer Surgery, University Hospital of Cologne, Kerpener Str. 62, Cologne 50937, Germany. ute.warnecke-eberz@uk-koeln.de
Research Domain of This Article
Oncology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 21, 2020; 26(23): 3236-3248 Published online Jun 21, 2020. doi: 10.3748/wjg.v26.i23.3236
Table 1 Demographics, therapy and prognosis of esophageal cancer patients
Total
ESCC
EAC
n
5Y-SR (%)
n
5Y-SR (%)
n
5Y-SR (%)
Total study cohort
195
27
90
27
105
26
Median age (yr)
60.4
-
60
-
62
-
Gender
Male
155
28
61
25
94
31
Female
40
26
29
32
11
12
Therapy
Surgery only
89
29
32
27
57
31
RTx/CTx + surgery
106
27
58
27
48
28
T-category
pT2
30
46
6
62
24
43
cT/pT3
165
25
84
24
81
26
Endoscopic biopsy
104
25
58
22
46
29
Table 2 Podoplanin expression in esophageal cancer squamous cell carcinoma of the esophagus vs adenocarcinoma of the esophagus
Total
ESCC
EAC
n
Podoplanin > 5% (HPE, %)
n
Podoplanin > 5% (HPE, %)
n
Podoplanin > 5% (HPE, %)
Total study cohort
195
13
90
26
105
2
Gender
Male
155
10
61
23
94
1
Female
40
25
29
32
11
9
Therapy
Surgery only
89
19
32
50
57
2
RTx/CTx + surgery
106
7
58
11
48
2
T-category
pT2
30
3
6
17
24
0
cT/pT3
165
14
84
27
81
3
Endoscopic biopsy
104
7
58
38
46
2
Table 3 Podoplanin expression and tumor progression
Resected tissue
Score
Podoplanin, %
Patients, n
Patients, %
pT2, n = 6
1
0-5
5
83
2
6-35
1
17
3
36-65
0
0
pT3/4, n = 26
1
0-5
11
43
2
6-35
10
38
3
36-65
5
19
pN0, n = 11
1
0-5
7
64
2
6-35
2
18
3
36-65
2
18
pN+, n = 21
1
0-5
9
43
2
6-35
9
43
3
36-65
3
14
Table 4 Expression of podoplanin protein differs between tissues resected from neoadjuvantly treated and non-pretreated direct surgery squamous cell carcinoma of the esophagus patients
Resected tissue
Podoplanin
Patients
Score
%
n
%
RTx/CTx + surgery
1
0-5
51
89
2
6-35
5
9
3
36-65
2
2
Primary surgery non-pretreated
1
0-5
16
50
2
6-35
11
34
3
36-65
5
16
Table 5 Podoplanin expression pre- and post-neoadjuvant chemoradiaton
Endoscopic biopsies pre RTx/CTx
Post RTx/CTx resected tissue
Podoplanin expression
Patients, n
0-5%
6%-35%
36%-65%
> 65%
0-5%
35
34
1
0
0
6%-35%
14
10
3
1
0
36%-65%
3
3
0
0
0
> 65%
4
3
1
0
0
Citation: Warnecke-Eberz U, Plum P, Schweinsberg V, Drebber U, Bruns CJ, Müller DT, Hölscher AH, Bollschweiler E. Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients. World J Gastroenterol 2020; 26(23): 3236-3248